


M M	lylan	Artwork Implementation Schedule				Date of Issue				Issued By						
Laboratories Limited Check (✓) whichever is applicable					Date of Return				255464 57							
					Material Code	750	083255	Supersede	s 75083156	Market	EMERGING					
[] New Component [] Immediately (Stock of superseded component to be destroyed, if applicable.) [] After consumption of existing (superseded) stock.						Description	СТ	CT MOLNATRIS CAPS 200 mg 40'S EM V1								
						Component	Prin	rinted Self Adhesive Label Actual Size 64 x 54 x 92 mm								
						Substrate	270 gsm ITC Cyber Plus Board with Spot Aqueous Varnish									
[] Other (Specify)																
						Design & Style	Su	Supply in Top opening Reverse Tuck-In								
					Reason for	Inclusion of Indications Warnings statement										
		Sign. dd/mm/yy		Sign. dd/mm/yy Job Function		Issue										
						Printing Pantone Nos	1	Black	2	306 c	3	295 c	4	Red 032 c		
		Job Function					5	NA	6	NA	7	NA	8	NA		
Proof No.	1	2	3	4	5	Non Printing	•	Die Lin	e 0	No Varnish	0	NA	0	NA		
Date	25.10.2021	26.10.2021	29.10.2021	08.11.2021	dd/mm/yy	Prepared By	Checked			ed By	Approved By					
	New Component	corrections	Red Box Included &	Included Indication	Х	Packaging Developmen	t	Packaging Development		Production		· · · · · · · · · · · · · · · · · · ·		Quality Assurance		
Remarks			Indication warning removed	warnings statement												
SOP-000565164-FORM-000565208-A01-03-01-20					1											



artwork - 150%

Each capsule contains: Molnupiravir 200 mg

Do not store above 30°C, store in original container.

Dosage: As directed by the physician. NOT TO EXCEED PRESCRIBED DOSAGE. KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.

Indications, Warnings & Precautions: Read the package leaflet before use.

MOLNATRIS is manufactured under a license from MERCK SHARP & DOHME SINGAPORE TRADING PTE. LTD

To be distributed and used in licensed countries only.

Molnupiravir Capsules

MOLNATRIS™

200 mg

ยาควบคุมพิเศษ

ใช้เฉพาะโรงพยาบาลและคลินิกเวชกรรม 40 Capsules



Imported by: Viatris Pharmaceuticals (Thailand) Limited, Bangkok, Thailand

Reg.No. 1C 44/65 (NG)

Mfg. Lic. No.: NKD/89

Mfd. by:

Mylan Laboratories Limited

F-4 & F-12, MIDC, Malegaon, Sinnar, Nashik - 422 113, Maharashtra, INDIA ™ Trademark under Registration

UNVARNISHED AREA (40 x 16 mm)

(without Background Color)

Mylan Laboratories Limited Artwork Implementation Sched Check (/) whichever is applica					plicable	Date of Issue Date of Return				Issued By					
Packaging Development (Approval is not valid without following details)						Material Code	75	083254	Supersede	s 75083155	Market	EMERGING			
[] New Component						Description	LBST MOLNATRIS CAPS 200 mg 40's EM V1								
[] Immediately (Stock of superseded component to be destroyed, if applicable.) [] After consumption of existing (superseded) stock.						Component	Prin	Printed Self Adhesive Label							
						Substrate	80 gsm Chromoart Paper + (62 gsm Silicon or 32 gsm PET Release Liner)								
[] Other (Specify)					+ 18 gsm Adhesive with spot aqueous varnish										
						Design & Style	Su	Supply In-Roll (Unwinding from Right to Left)							
					Reason for	Inclusion of Indications Warnings statement									
		Sign. dd/mm/yy		Sig		Issue									
				dd/mm/yy Job Function		Printing Pantone Nos	1	Black	2	306 c	3	295 с	4	Red 032 c	
Job Function		Job Function					5	NA	6	NA	7	NA	8	NA	
Proof No.	1	2	3	4	5	Non Printing	•	Die Line	e 0	No Varnish	0	NA	0	NA	
Date	25.10.2021	26.10.2021	29.10.2021	08.11.2021	dd/mm/yy	Prepared By	Checked			d By	Approved By				
	New Component	corrections	Red Box Included &	Included Indication	Х	Packaging Development		Packaging Development		Production		, ,		Quality Assurance	
Remarks			Indication warning removed	warnings statement											
SOP-000565164-FORM-000565208-A01-03-01-20					1										